Patients and inclusion and exclusion criteria
diarrhea, Nordisk A/S, rash, constipation, dizziness, satiety, hematoma, weight loss, dyspeptic symptoms, nausea, vomiting
HEMATOMA, INJECTION SITE REACTION, LOSS OF APPETITE
The trial enrolled 103 patients of both sexes aged ≥ 21 years, with a BMI (BMI = body mass divided by the square of the body height) of 30 kg/mLiraglutide is marketed under the trade name Saxenda by Novo Nordisk A/S (Bagsværd, Denmark) and Novo Nordisk Pharmaceutical Industries LP (Clayton, USA). Neither company was involved in this study, or supported it in any manner, or had access to the study data. The compound, a GLP-1 receptor agonist, reduces the appetite and, consequently, reduces food ingestion, promoting weight loss. The drug can cause nausea, vomiting, diarrhea, constipation, loss of appetite, dyspeptic symptoms, sensation of weakness, injection site reactions (hematoma, irritation, rash) and dizziness, among other effectsSibutramine hydrochloride monohydrate is an anti-obesity drug which acts primarily through its active metabolites monodesmethyl (M1) and didesmethyl (M2) by effectively blocking the recapture of serotonin (5-hydroxytryptamine), norepinephrine and dopamine. The compound inhibits the appetite by promoting a sensation of satiety and diminishes weight loss-induced decline in energy expenditureThe general exclusion criteria were age < 21 years, BMI < 30 kg/m